Allovate Therapeutics Announces Issuance of Second Japanese Patent, Expanding Global Coverage of the Oral Mucosal Immunotherapy Platform

New York, March 21, 2018 --

Allovate Therapeutics, a biopharmaceutical company focused on improving treatment options for allergies, announced today that the Japan Patent Office (JPO) has recently issued patent number JP6239066 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” This new patent includes claims to additional oral compositions that can be combined with allergens and used to administer immunotherapy via contact with oral tissues.  

This patent provides expanded patent protection for Allovate’s oral mucosal immunotherapy (OMIT) platform in Japan. It is the second OMIT patent issued in Japan. Allovate’s IP portfolio also includes issued patents in the United States and Australia.    

Dr. Erick Berglund, Co-Founder and CEO of Allovate Therapeutics, said, “the issuance of this latest patent is important because Japan is one of the key markets for allergy immunotherapy that we have identified for OMIT products. Almost 40% of the population of Japan suffer symptoms of allergic rhinitis. The majority of these patients are sensitized to the pollen of Japanese Cedar trees, which populate the country in great numbers and release enormous amounts of pollen for several weeks every spring."

Allovate^® is assembling a global patent portfolio to develop OMIT products that target the unique needs of respiratory allergy populations in different areas around the world. The OMIT platform is also expected to have potential for treating food allergy, a potentially deadly disorder for which there are currently no regulatory-approved treatment options. Allovate^® has licensed commercialization rights for food allergy OMIT products to Intrommune Therapeutics, which will focus initially on an FDA-approved treatment for peanut allergy.

About Oral Mucosal Immunotherapy (OMIT)

Oral mucosal immunotherapy (OMIT) uses a proprietary, specially formulated toothpaste to incorporate and stabilize allergenic proteins that are administered while a user brushes their teeth, delivering allergen-specific immunotherapy to the areas of the oral cavity with the highest density of the immune cells responsible for initiating desensitization. OMIT simplifies long-term daily adherence to immunotherapy for patients, offering a potential solution to the “crisis of compliance” in allergy immunotherapy.

Allergen-specific immunotherapy is the only treatment method that targets the root cause of allergies. Immunotherapy has been administered in the past by injecting allergens into the skin (subcutaneous immunotherapy) or placing them under the tongue (sublingual immunotherapy). Respiratory allergies affect at least 60 million people in the United States, 40-50 million people in Japan, and 160 million in European. Symptomatic treatment, at a global cost of over $25 billion yearly, does not offer a long-term solution.


About Allovate Therapeutics

Allovate Therapeutics is a New York City-based biopharmaceutical company founded in 2012 to improve allergy treatment for all patients. Allovate’s aim is to provide safe, effective, and convenient new options for allergy sufferers that deliver demonstrable improvements to therapeutic adherence and clinical outcomes over existing allergy treatment protocols. Allovate’s lead product, Allerdent^®, is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth.

For more information, please visit www.allovate.com.

For more information, please contact:
Michelle Mantia
Outreach Manager
Allovate Therapeutics
[email protected]